Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer
- Advanced Squamous Non-Small Cell Lung Carcinoma
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Metastatic Squamous Non-Small Cell Lung Carcinoma
- Non-small Cell Lung Cancer
- Non-small Cell Lung Cancer Stage III
- Non-small Cell Lung Cancer Stage IV
- Non-small Cell Lung Cancer Recurrent
Interventions
- BIOLOGICAL: Olvimulogene nanivacirepvec
- DRUG: Platinum chemotherapy: carboplatin or cisplatin
- DRUG: Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC
- DRUG: Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab
- DRUG: Docetaxel
Sponsor
Genelux Corporation
Collaborators